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interquartile  range  [IQR],  88  to 
215  cells/μl; P  =  0.03, Wilcoxon 









































Baseline characteristics of study population
Measurement	 3-μg/kg	dose	 10-μg/kg	dose	 Overall
n 6 8 14
Age (yr) 46 (33; 65) 46 (29; 61) 46 (29; 65)
BMI (kg/cm2)A 24.53 (19.47; 27.99) 22.28 (18.75; 33.30) 23.52 (18.75; 33.30)
Time since HIV infection (yr)A 8 (4; 15) 7 (3; 20) 8 (3; 20)
Time since c-ART (yr)A 8 (4; 15) 6 (2; 16) 7 (2; 16)
Total CD4+ T cells, prior 6 mo (U/μl)B 214 (127; 275) 266 (142, 316) – 
Total CD4+ T cells (U/μl) 217 (107; 289) 237 (160; 312) 230 (107; 312)
Total CD8+ T cells (U/μl) 848 (249; 1,245) 574 (226; 790) 606 (226; 1,245)
Nadir CD4+ T cell (U/μl) 44 (1; 69) 45 (6; 137) 44 (1; 137)
HIV-1 DNA (log10 copies/106 CD4+ cells) 3.3 (ND; 3.9) 3.3 (ND; 4.5) 3.3 (ND; 4.5)
HIV-1 mRNA <50 copies/ml (n) 6 7 13
HIV-1 mRNA >50 copies/ml (n) 0 1C 1
Median values are shown, with minimum and maximum values shown in parentheses. ADerived data. BTotal 
cells within the last 6 mo prior to study entry. CPatient withdrawn after a single dose with 130 copies/ml (proto-
col deviation). ND, not detectable (for HIV-1 RNA, the limit of quantification was 50 copies/ml).
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Effects of rhIL-7 therapy on periph-
eral blood lymphocyte subsets. The 
absolute lymphocyte count from 
complete blood counts and flow 
cytometry–based frequency were 
used to determine evolution of (A) 
absolute counts of CD3+ T cells, 
CD3+CD4+ T cells, and CD3+CD8+ 
T cells; (B) absolute counts of 
mature B cells and percentages of 
pro-B and transitional B cells; (C) 
absolute counts of NK and NKT 
cells; and (D) fold increase from 
baseline of CD4+ and CD8+ T cells 
expressing CD127. Mean ± SEM for 
each cohort is shown. *P < 0.05 ver-
sus 0 d; Wilcoxon test.
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Changes from baseline characteristics
Measurement	 	 3-μg/kg	dose	 	 	 10-μg/kg	dose	
	 14	d	 28	d	 12	wk	 14	d	 28	d	 12	wk
CD4+	T	cells
Total 158A (83; 215) 118A (81; 293) 101A (35; 124) 752A (207; 1,152) 576A (186; 793) 385A (77; 513) 
NB 8A (4; 39) 7A (3; 84) 6A (–5; 40) 91A (57; 284) 108A (28; 301) 71A (32; 143) 
CMC 73A (50; 155) 44A (26; 160) 20A (–43; 92) 364A (130; 772) 349A (92; 426) 184A (28; 377) 
EMD 44 (21; 63) 46 (37; 93) 35A (6; 125) 140A (9; 319) 137A (29; 167) 58A (18; 81) 
EE 24 (1; 26) 6 (–9; 29) 5 (–2; 18) 12A (0; 26) 2A (0; 25) 0 (0; 12) 
TEF 0 (–11; 7) 0 (–9; 19) 0 (–17; 18) 2 (–1; 11) 0 (–11; 35) 1 (–17; 47) 
RTEG 7 (–4; 24) 7A (2; 71) 5 (–2; 29) 9A (3; 9) 17A (0; 51) 6 (–2; 13) 
Activated (%)H 2 (–1; 2) 1 (0; 4) 0 (–3; 2) 0 (–1; 2) 0 (–1; 6) –1 (–2; 1) 
Ki67+ (%) 2A (–3; 8) –1 (–2; 2) –1 (–2; 1) 3A (0; 4) –1 (–2; –1) 0 (–2; 2) 
CD8+	T	cells
Total 290A (96; 666) 494A (–662; 664) 203A (65; 555) 1,040A (191; 2,194) 996A (534; 1,783) 464A (416; 848) 
NB 80 (63; 231) 118 (–46; 329) 130 (30; 189) 458A (62; 1371) 491A (162; 1,520) 318A (109; 575) 
CMC 125 (27; 269) 36 (–301; 282) 55 (35; 199) 224A (31; 1,562) 328A (67; 723) 165A (–21; 509) 
EMD –1 (–21; 4) –2 (–57; 28) 9 (–4; 81) 7 (–12; 49) 12 (–11; 178) 13 (–11; 61) 
EE 50 (3; 77) –8 (–163; 191) –2 (–38; 105) 20A(–32; 199) 22 (–29; 198) –6 (–77; 71) 
TEF 32 (–71; 76) 88 (–190; 112) 10 (–10; 28) 35 (–60; 55) 42 (–51; 131) 46 (–54; 90) 
Activated (%)H 0 (–3; 10) 1 (–2; 12) 1 (–4; 6) 1 (–3; 8) 1 (–1; 6) –1 (–7; 2) 
Ki67+ (%) Not done Not done Not done 3A (0; 4) –1 (–1; 0) 0 (–1; 0) 
B	cells
TotalI –9 (–39; 130) 33 (–37; 241) 79 (–5; 192) –21 (–132; 65) 26 (–313; 66) 55 (–109; 302) 
Pro-B (%)J 0 (0; 0) 0 (0; 0) 0 (0; 0) 0 (0; 0) 0 (0; 0) 0 (0; 0) 
Activated (%)K 0 (–5; 2) 8 (–4; 23) 5 (–2; 15) 4 (–31; 10) 16 (–10; 62) 7 (–12; 40) 
Other
NK cellsL 52 (–38; 68) 54 (–154; 122) 12 (–310; 57) 58A (–156; 81) 41A (15; 469) 47 (–76; 393) 
NKT cellsM 23 (–34; 93) 36 (12; 122) 13 (–146; 83) 71A (–23; 92) 59A (15; 469) 65 (–4; 393)
Median change relative to baseline is shown, with minimum and maximum values shown in parentheses. Values are cells/μl unless otherwise indicated.  
AP < 0.05 versus baseline; Wilcoxon test. BNaive subset (CD45RA+CD27+CD28+). CCentral memory subset (CD45RA–CD27+CD28+). DEffector memory 
subset (CD45RA–CD27–CD28+). EEffector subset (CD45RA–CD27–CD28–). FTerminally differentiated effector subset (CD45RA+CD27–CD28–). GRTE 
subset (CD4+CD45RA+CD27+CD31hi). HClassified as HLA-DR+CD38+. IClassified as CD34–CD19+. JClassified as CD34+CD19+. KClassified as CD34–
CD19+CD10+. LClassified as CD3–CD56+. MClassified as CD3+CD56+.
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Effects of rhIL-7 therapy on T cell function. In order to determine 
whether these changes in lymphocyte phenotype were associated 
Figure 
CD4+ T cell count prior to rhIL-7 treatment predicts the magnitude of CD4+ T cell increase after rhIL-7 treatment. The linear correlation between 
CD4+ T cell count before treatment at 0 d and 12 wk relative to rhIL-7 treatment initiation at each dose is shown. Overall regression using a 
Spearman test showed a significant correlation between CD4+ T cell counts at entry CD4+ T cell responses in both groups and in the global 
population of IL-7–treated patients.
Figure 
rhIL-7 therapy induces a preferential increase of naive and central memory CD4+ and CD8+ T cells. (A) Representative flow cytometry analysis 
of CD4+ and CD8+ T cell populations from a single representative subject treated at the 3-μg/kg dose. Numbers within the plots indicate the 
percent of each T cell population: naive (N; CD45RA+CD27+), central memory (CM; CD45RA–CD27+), effector memory and effector (EM+E; 
CD45RA–CD27–), terminally differentiated effector (TE; CD45RA+CD27–), and RTE (CD45RA+CD31hi). (B) Time evolution of CD4+ and CD8+ 
T cell subsets. Mean ± SEM for each cohort is shown. *P < 0.05 versus 0 d; Wilcoxon test.
research article





































rhIL-7 therapy is not associated with T cell activation, but increases T cell cycling. Analyses were performed in patients treated with the 10-μg/kg 
dose of rhIL-7. (A and B) Percent cells in CD4+ (A) and CD8+ (B) T cell subpopulations expressing Ki67 via flow cytometry. Mean ± SEM for 
each T cell subset is shown. Ki67 expression significantly increased at 14 d. (C) Percent CD4+ and CD8+ activated T cells (HLA-DR+CD38+). 
Error bars denote SD. *P versus 0 d; Wilcoxon test.
Figure 
rhIL-7 expanded T cells respond to polyclonal and antigenic stimula-
tion. PBMCs were collected at the indicated time points, cryopreserved, 
and then thawed before analysis. (A) Proliferation in response to TCR 
stimulation (anti-CD3 plus anti-CD28) was measured by [3H] incorpo-
ration. Similar proliferation levels were observed at each time point. 
Error bars denote SD. (B) Both CD4+ and CD8+ T cells produced IFN-γ 
and IL-2 in response to SEB at levels comparable to baseline 28 d 
and 12 wk after rhIL-7 therapy. Analyses were performed in patients 
treated with 10 μg/kg rhIL-7. Error bars denote SD. (C) rhIL-7 therapy 
increased the capacity of CD4+ T cells to respond to HIV Gag and CMV 
antigens by secreting IFN-γ and/or IL-2. All 7 patients treated with 10 
μg/kg rhIL-7 were analyzed.
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HIV plasma viral load values throughout the study in individual 
patients
Patient	no.	 –7	d	 7	d	 14	d	 21	d	 28	d	 9	wk	 12	wk
3-μg/kg	dose
401 – – – – – – –
301 – – – – – – –
302 – – – – – – –
101 – – – – – – –
303 – – – – – – –
501 – – – – – – –
10-μg/kg	dose
502 – 550 180 60 – – 120
603 – – 110 – – – 74
102 – 220 – – – – –
203 – – – 500 – – 630
201 – – – – – – –
204 – – – – – – –
206 – – – – – – –
Shown are HIV plasma viral load values (copies/ml) for the transient 
blips of viral replication observed in 4 patients at the 10-μg/kg dose. 
These patients had detectable HIV Gag-specific CD4+ T cell responses, 
as assessed via flow cytometry in Figure 5C. All other values (–) were 
below the 50 copies/ml threshold for plasma HIV-RNA detection.
Table 
Changes in viral load in PBMC and CD4+ cell populations
	 3-μg/kg	dose	 10-μg/kg	dose
Cell	population	 21	d	 12	wk	 21	d	 12	wk
PBMCs +0.2 +0.2 +0.2 +0.2
CD4+ cells +0.0 +0.2 +0.0 –0.1
Values denote median change relative to baseline in HIV-1 DNA provi-
ral load (log10 copies per 106 cells of the indicated population).
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active  antiretroviral  therapy. Ann. Intern. Med. 
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